Current Report Filing (8-k)
30 Mai 2023 - 01:01PM
Edgar (US Regulatory)
0000946644
false
0000946644
2023-05-22
2023-05-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report May 22, 2023
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-27072 |
|
52-0845822 |
(state
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2117
SW Highway 484, Ocala FL |
|
34473 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
ImmunoTech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
AIM |
|
NYSE
American |
Item 1.01 Entry into a material definitive agreement.
On
May 22, 2023, AIM ImmunoTech Inc. (the “Company”) and the Japanese National Institute of Infectious Disease (the “JNIID”)
entered into a Material Transfer and Research Agreement (the “Agreement). Pursuant to the “Agreement, the JNIID will conduct
research on Ampligen’s capacity to prevent viral shedding in respiratory virus infections (the “Research Project”).
The Company will supply JNIID, free of charge with sufficient quantities of Ampligen to conduct the Research Project. Each party will
retain the rights to its own intellectual property and ownership of intellectual property arising out of the Research Project shall follow
inventorship under U.S. patent and trademark law. Should the results of the Research Agreement be favorable, the parties would need to
enter into a license agreement to proceed further. The Agreement will terminate upon the earlier of: the completion of the Research Project,
written agreement signed by authorized representative of the Company, or one year from the effective date of that agreement. The parties
also entered into a mutual confidentiality agreement.
The
foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text
of the Agreement, a copy of which is filed hereto as Exhibit 10.1.
Forward-Looking
Statements
This
current report on Form 8-K (including the Exhibits filed herewith) contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 (“PSLRA”). Words such as “may,” “will,” “expect,”
“plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events
or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks
and uncertainties, including whether the Research Project will generate positive results and whether the parties will proceed further.
Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in
the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur
after the date hereof. The information found on the Company’s website is not incorporated by reference into this press release
and is included for reference purposes only.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
EXHIBIT
INDEX
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
AIM
IMMUNOTECH INC. |
|
|
|
May
30, 2023 |
By: |
/s/
Thomas K. Equels |
|
|
Thomas
K. Equels, CEO |
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
AIM ImmunoTech (AMEX:AIM)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024